遗传性长QT综合征的药物及器械治疗

刘红彬

实用心电与临床诊疗 ›› 2016, Vol. 25 ›› Issue (5) : 309-312.

PDF(880 KB)
中国学术期刊综合评价数据库统计源期刊
中国学术期刊影响因子统计源期刊
中国生物医学文献数据库(CBM)收录期刊
PDF(880 KB)
实用心电与临床诊疗 ›› 2016, Vol. 25 ›› Issue (5) : 309-312. DOI: 10.13308/j.issn.2095-9354.2016.05.002
专题笔谈-长QT综合征

遗传性长QT综合征的药物及器械治疗

作者信息 +

Drug and device therapies of congenital longQT syndrome

Author information +
文章历史 +

摘要

遗传性长QT综合征(longQT syndrome,LQTS)以心电图上QT间期延长及其相关的尖端扭转型室性心动过速(torsade de pointes,TdP)为特征,易导致心脏性猝死。它的危险因素有QTc长度、基因型、晕厥史等。LQTS的治疗手段包括β受体阻滞剂治疗、外科心脏左侧交感神经节切除术(LCSD)、心脏起搏治疗以及植入式心律转复除颤器(ICD)治疗。β受体阻滞剂治疗是LQTS治疗的基石;心脏起搏治疗适用于伴有心动过缓的LQTS,可明显降低心脏事件的复发率,但不降低死亡率。对高危的LQTS应植入ICD,皮下ICD并发症较少,值得推广。LCSD技术实用性较差,更适用于ICD植入后频繁电击治疗的患者.

Abstract

Congenital longQT syndrome(LQTS) is characterized by the prolongation of QT interval in ECG and relevant torsade de pointes(TdP), which easily leads to sudden cardiac death. Its risk factors include the length of QTc interval, genotype, medical history of syncope, etc. The treatment of congenital LQTS involves β blockers, surgical left cardiac sympathetic denervation(LCSD), cardiac pacing and implantable cardioverter defibrillators(ICD). β blockers are the firstline treatment for all the LQTS patients. Cardiac pacing therapy is fit for LQTS patients complicating bradycardia, which can significantly reduce the recurrence rate of cardiac events, but not the mortality. Highrisk LQTS patients should be implanted with ICD. Less subcutaneous complications of ICD are found and thus the therapy is worthy of being promoted. LCSD is poorly practical and is more suitable for those ICDimplanted patients frequently undergoing electroshock.

关键词

遗传性 / 长QT综合征 / &beta / 受体阻滞剂 / 心脏起搏 / 植入式心律转复除颤器

Key words

heredity / long QT syndrome / &beta / blockers / pacing / implantable cardioverter defibrillator

引用本文

导出引用
刘红彬. 遗传性长QT综合征的药物及器械治疗[J]. 实用心电学杂志, 2016, 25(5): 309-312 https://doi.org/10.13308/j.issn.2095-9354.2016.05.002
LIU Hong-Bin. Drug and device therapies of congenital longQT syndrome[J]. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2016, 25(5): 309-312 https://doi.org/10.13308/j.issn.2095-9354.2016.05.002

参考文献

[1] 李翠兰,胡大一.心脏离子通道病引起的晕厥[J].心血管病学进展,2006,27(4):407-412.

[2] Schwartz PJ. Pharmacological and nonpharmacological management of the congenital long QT syndrome: the rationale[J]. Pharmacol Ther,2011,131(1):171-177.

[3] Priori SG,Schwartz PJ,Napolitano C,et al. Risk stratification in the longQT syndrome[J]. N Engl J Med,2003,348(19):1866-1874.

[4] Sauer AJ,Moss AJ,McNitt S,et al. Long QT syndrome in adults[J]. J Am Coll Cardiol,2007,49(3):329-337.

[5] Goldenberg I,Moss AJ,Peterson DR,et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital longQT syndrome[J]. Circulation,2008,117(17):2184-2191.

[6] Goldenberg I,Zareba W,Moss AJ. Long QT syndrome[J]. Curr Probl Cardiol,2008,33(11):629-694.

[7] [JP4]Moss AJ,Shimizu W,Wilde AA,et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene[J]. Circulation,2007,115(19): 2481-2489.

[8] Shimizu W,Moss AJ,Wilde AA,et al. Genotypephenotype aspects of type 2 long QT syndrome[J]. J Am Coll Cardiol,2009,54(22):2052-2062.

[9] Migdalovich D,Moss AJ,Lopes CM,et al. Mutation and genderspecific risk in type 2 long QT syndrome: implications for risk stratification for life threatening cardiac events in patients with long QT syndrome[J]. Heart Rhythm,2011,8(10):1537-1543.

[10] Schwartz PJ,Spazzolini C,Priori SG,et al. Who are the longQT syndrome patients who receive an implantable cardioverterdefibrillator and what happens to them? data from the european longQT syndrome implantable cardioverterdefibrillator (LQTS ICD) registry[J]. Circulation,2010,122(13):1272-1282.

[11] Vincent GM,Schwartz PJ,Denjoy I,et al. High efficacy of betablockers in longQT syndrome type 1: contribution of noncompliance and QTprolonging drugs to the occurrence of betablocker treatment “failures” [J]. Circulation,2009,119(2):215-221.

[12] Chockalingam P,Crotti L,Girardengo G,et al. Not all betablockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol[J]. J Am Coll Cardiol,2012,60(20):2092-2099.

[13] Goldenberg I,Bradley J,Moss A,et al. Betablocker efficacy in highrisk patients with the congenital longQT syndrome types 1 and 2: implications for patient management[J]. J Cardiovasc Electrophysiol,2010,21(8):893-901.

[14] Schwartz PJ,Priori SG,Cerrone M,et al. Left cardiac sympathetic denervation in the management of highrisk patients affected by the longQT syndrome[J]. Circulation,2004,109(15):1826-1833.

[15] Epstein AE,DiMarco JP,Ellenbogen KA,et al.2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for devicebased therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2013,61(3):e6-e75.

[16] 李国栋,郑燕列.倍他乐克联合起搏器植入对长QT综合征并发尖端扭转性室速的疗效观察[J]. 现代医学,2016,4(2) : 245-247.

[17] 陈旭华,浦介麟,王靖,等.永久起搏器和埋藏式心脏复律除颤器(ICD)在遗传性长QT综合征患者中的应用[J].中国分子心脏病学杂志,2014,14(3):945-948.

[18] Jons C,Moss AJ,Goldenberg I,et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope[J]. J Am Coll Cardiol,2010,55(8):783-788.

[19] Schwartz PJ,Spazzolini C,Crotti L,et al. The Jervell and LangeNielsen syndrome: natural history, molecular basis, and clinical outcome[J]. Circulation,2006,113(6):783-790.

[20] Dorostkar PC,Eldar M,Belhassen B,et al. Long term followup of patients with long-QT syndrome treated with betablockers and continuous pacing[J]. Circulation,1999,100(24):2431-2436.

[21] Burke MC,Gold MR,Knight BP,et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2year results from a pooled analysis of the IDE study and EFFORTLESS registry[J]. J Am Coll Cardiol,2015,65(16):1605-1615.

PDF(880 KB)

86

Accesses

0

Citation

Detail

段落导航
相关文章

/